1. Home
  2. News
  3. Chimeric Therapeutics Limited
  4. Positive pre-IND meeting with FDA for Phase 1 CAR T study
More Chimeric Therapeutics Limited news
Chimeric Therapeutics LimitedASX: CHM

Positive pre-IND meeting with FDA for Phase 1 CAR T study

Mar 20, 2023 at 11:16 PM EDT · Issued by Chimeric Therapeutics Limited

Filed with ASX · Mar 20, 2023 at 11:16 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/positive-pre-ind-meeting-with-fda-for-phase-1-car-t-study

Chimeric Therapeutics Limited on 6ix

Story so far

  • Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trialDec 22, 2022
  • CDH17 CAR t preclinical data featured in Nature CancerMar 23, 2022
  • Encouraging data from 2nd dose cohort in CLTX CAR T trialFeb 8, 2022

Earlier from Chimeric Therapeutics

  • Fourth dose cohort initiated in CHM 1101 Phase 1 trialMar 2, 2023
  • Appendix 4D and Half Year ReportFeb 28, 2023
  • Chimeric receives $3.06M R&D tax incentiveFeb 14, 2023
  • Follow up period completed for 3rd cohort in CHM 1101 trialJan 22, 2023
  • Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trialDec 21, 2022

Later from Chimeric Therapeutics

  • CHM 1101 GBM Abstract Accepted for ASCO 2023 PresentationApr 3, 2023
  • Phase 1B brain cancer clinical trial approved for initiationApr 25, 2023
  • New CLTX CAR technology patent protection in India & IsraelApr 28, 2023
  • Board & management commit to $1M placement and proposed SPPMay 15, 2023
  • SPP offer documents issued to shareholdersMay 22, 2023
All Chimeric Therapeutics news releases↗

Follow Chimeric Therapeutics into a list and get an email when it puts out news.

Follow Chimeric Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer